Should I buy or sell Matinas BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares. View MTNB analyst ratings or view top-rated stocks .

What is Matinas BioPharma's stock price target for 2024?

1 Wall Street analysts have issued 1 year price objectives for Matinas BioPharma's stock. Their MTNB share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,381.5% from the stock's current price. View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts .

How have MTNB shares performed in 2024?

Matinas BioPharma's stock was trading at $0.2801 at the beginning of the year. Since then, MTNB stock has decreased by 27.7% and is now trading at $0.2025. View the best growth stocks for 2024 here .

Are investors shorting Matinas BioPharma?

Matinas BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,270,000 shares, an increase of 147.7% from the March 15th total of 1,320,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is presently 2.2 days. View Matinas BioPharma's Short Interest .

When is Matinas BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our MTNB earnings forecast .

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.03) EPS for the quarter.

What other stocks do shareholders of Matinas BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB) , Gran Tierra Energy (GTE) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Pennsylvania Real Estate Investment Trust (PEI) , CNBX Pharmaceuticals (CNBX) , Organigram (OGI) , Novan (NOVN) , Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS) .

How do I buy shares of Matinas BioPharma?

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NYSEAMERICAN:MTNB

Matinas BioPharma (MTNB) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free MTNB Stock Alerts

$0.20

0.00 (0.00%)

(As of 04/15/2024 ET)

Compare

Today's Range: $0.20
▼
$0.21
50-Day Range: N/A
52-Week Range: $0.11
▼
$0.89

Volume: 822,465 shs
Average Volume: 1.45 million shs
Market Capitalization: $44.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Stock Analysis Analyst Forecasts Chart Earnings Headlines Ownership Short Interest

Get Matinas BioPharma alerts:

Matinas BioPharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,381.5% Upside
$3.00 Price Target
Short Interest: Healthy
1.50% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.86 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Matinas BioPharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Matinas BioPharma has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.50% of the outstanding shares of Matinas BioPharma have been sold short.
Short Interest Ratio / Days to Cover
Matinas BioPharma has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Matinas BioPharma has recently increased by 147.73%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Matinas BioPharma does not currently pay a dividend.
Dividend Growth
Matinas BioPharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for MTNB.

0.6

News and Social Media Coverage

News Sentiment
Matinas BioPharma has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Matinas BioPharma this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for MTNB on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Matinas BioPharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.60% of the stock of Matinas BioPharma is held by insiders.
Percentage Held by Institutions
Only 11.77% of the stock of Matinas BioPharma is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Matinas BioPharma is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Matinas BioPharma is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Matinas BioPharma has a P/B Ratio of 2.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

“Forget Tesla, this is Elon’s Next Big Thing”

According to Forbes, this breakthrough could define the future of AI. Most people don’t know about it… Because it was found 750 miles away from Silicon Valley.

Click here to see the details.

About Matinas BioPharma Stock (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.

MTNB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MTNB Stock News Headlines

April 3, 2024 | msn.com

Matinas Declines on Public Offering

April 3, 2024 | globenewswire.com

Matinas BioPharma Prices $10 Million Registered Direct Offering

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

Sam Altman, the CEO of OpenAI, has invested $375 million into a breakthrough technology, that legendary financial analyst Porter Stansberry believes… …could be the number-one investment of the decade.

April 1, 2024 | finance.yahoo.com

Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript

March 28, 2024 | finanznachrichten.de

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

March 28, 2024 | finance.yahoo.com

Q4 2023 Matinas BioPharma Holdings Inc Earnings Call

March 27, 2024 | investorplace.com

MTNB Stock Earnings: Matinas BioPharma Hldgs Reported Results for Q4 2023

March 27, 2024 | globenewswire.com

Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update

April 16, 2024 | Porter & Company (Ad)

The #1 Investment of the Decade…

March 25, 2024 | finanznachrichten.de

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

March 25, 2024 | globenewswire.com

Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation

March 22, 2024 | finance.yahoo.com

Why Is Fungal Infections-Focused Matinas BioPharma Stock Trading Higher On Friday?

March 22, 2024 | finance.yahoo.com

Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

March 22, 2024 | globenewswire.com

Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response

March 22, 2024 | globenewswire.com

Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards

March 3, 2024 | uk.finance.yahoo.com

Matinas BioPharma Holdings, Inc. (MTNB)

February 28, 2024 | wsj.com

Matinas BioPharma Holdings Inc.

February 26, 2024 | finance.yahoo.com

Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution

February 23, 2024 | benzinga.com

Matinas BioPharma Hldgs Stock (AMEX:MTNB) Dividends: History, Yield and Dates

February 20, 2024 | finance.yahoo.com

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

February 20, 2024 | globenewswire.com

Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis

February 4, 2024 | seekingalpha.com

AVBP ArriVent BioPharma, Inc.

January 21, 2024 | morningstar.com

Matinas BioPharma Holdings Inc MTNB

January 3, 2024 | finance.yahoo.com

Matinas BioPharma to Present at Biotech Showcase 2024

December 27, 2023 | finance.yahoo.com

Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

December 21, 2023 | finanznachrichten.de

Matinas BioPharma Holdings, Inc.: Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA

December 21, 2023 | markets.businessinsider.com

Matinas BioPharma Plans To Meet With FDA In Q1 To Finalize Phase 3 Protocol For MAT2203

See More Headlines

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/27/2024
Today: 4/15/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NYSEAMERICAN:MTNB
CUSIP: N/A
CIK: N/A
Web: www.matinasbiopharma.com
Phone: (908) 484-8805
Fax: N/A
Employees: 34
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.00
High Stock Price Target: $3.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +1,381.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-22,940,000.00
Net Margins: N/A
Pretax Margin: -2,093.25%
Return on Equity: -89.20%
Return on Assets: -72.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.93
Quick Ratio: 5.93

Sales & Book Value

Annual Sales: $1.10 million
Price / Sales: 40.04
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.09 per share
Price / Book: 2.25

Miscellaneous

Outstanding Shares: 217,480,000
Free Float: 196,605,000
Market Cap: $44.04 million
Optionable: Not Optionable
Beta: 1.52

(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Mr. Jerome D. Jabbour J.D. (Age 50)
Co-Founder, CEO, President & Director
Comp: $881.5k
Dr. Theresa Matkovits Ph.D. (Age 57)
Chief Development Officer
Comp: $601k
Dr. James J. Ferguson FACC (Age 70)
M.D., Chief Medical Officer
Comp: $619.92k
Mr. Keith A. Kucinski CPA (Age 54)
M.B.A., Chief Financial Officer
Comp: $249.05k
Dr. Hui Liu M.B.A. (Age 56)
Ph.D., Chief Technology Officer
Mr. Frank Calamusa
Executive Director and Head of Manufacturing & Supply Chain
Mr. Thomas J. Hoover M.B.A. (Age 54)
Chief Business Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

MTNB Stock Analysis - Frequently Asked Questions

Should I buy or sell Matinas BioPharma stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MTNB shares.
View MTNB analyst ratings or view top-rated stocks.
What is Matinas BioPharma's stock price target for 2024?: 1 Wall Street analysts have issued 1 year price objectives for Matinas BioPharma's stock. Their MTNB share price targets range from $3.00 to $3.00. On average, they expect the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,381.5% from the stock's current price.
View analysts price targets for MTNB or view top-rated stocks among Wall Street analysts.
How have MTNB shares performed in 2024?: Matinas BioPharma's stock was trading at $0.2801 at the beginning of the year. Since then, MTNB stock has decreased by 27.7% and is now trading at $0.2025.
View the best growth stocks for 2024 here.
Are investors shorting Matinas BioPharma?: Matinas BioPharma saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,270,000 shares, an increase of 147.7% from the March 15th total of 1,320,000 shares. Based on an average daily trading volume, of 1,520,000 shares, the short-interest ratio is presently 2.2 days.
View Matinas BioPharma's Short Interest.

When is Matinas BioPharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our MTNB earnings forecast.
How were Matinas BioPharma's earnings last quarter?: Matinas BioPharma Holdings, Inc. (NYSEAMERICAN:MTNB) announced its quarterly earnings data on Wednesday, March, 27th. The company reported ($0.03) EPS for the quarter.
What other stocks do shareholders of Matinas BioPharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Matinas BioPharma investors own include KushCo (KSHB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), Organigram (OGI), Novan (NOVN), Zosano Pharma (ZSAN) and Aeterna Zentaris (AEZS).
How do I buy shares of Matinas BioPharma?: Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:MTNB) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial